Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 44Neoplasms, Plasma Cell 10Neoplasms 3Vomiting 2Recurrence 2Lung Neoplasms 2Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Nausea 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Magnetic Resonance Spectroscopy 3Prednisone 2Positron-Emission Tomography 2Lenalidomide 2Injections 2Dexamethasone 2Cyclophosphamide 2technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1obinutuzumab 1lortalamine 1fluciclovine F-18 1Vindesine 1Vincristine 1Transplantation, Autologous 1Thalidomide 1Rituximab 1Mitomycin 1Melphalan 1Doxorubicin 1Diagnosis 1Bleomycin 13-Iodobenzylguanidine 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Disease × Thalidomide × Clear all
NCT00232934 2018-08-02

Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Gruppo Italiano per lo Studio del Mieloma Multiplo

Phase 3 Completed
400 enrolled
Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡